Table 2.
Summary of clinical inputs (cure, recurrence), adverse events and mortality included in the model
| Item | EPFX | Vancomycin |
|---|---|---|
| Clinical cure, % [20] | N = 177 | N = 179 |
| Clinical cure 2 days after EOT | 78.0 | 82.1 |
| Risk of recurrence, % [20] | N = 138 | N = 147 |
| Recurrence at day 40 | 1.4 | 19.7 |
| Recurrence at day 55 | 4.3 | 21.1 |
| Recurrence at day 90 | 7.2 | 22.4 |
| Incidence of adverse events, % [20] | N = 181 | N = 181 |
| Anaemia | 2.8 | 5.5 |
| Heart failure | 2.2 | 5.5 |
| Constipation | 5.5 | 2.8 |
| Diarrhoea | 5.5 | 6.6 |
| Fever | 3.9 | 6.6 |
| CDI | 3.9 | 13.3 |
| Pneumonia | 2.8 | 5.5 |
| Sepsis | 0.6 | 5.0 |
| Urinary tract infection | 3.3 | 6.6 |
| Mortality, % [20] | N = 183 | N = 181 |
| Days 0–10 | 1.4 | |
| Days 11–15 | 1.3 | |
| Days 16–25 | 1.2 | |
| Days 26–30 | 1.0 | |
| Days 31–90 | 0.9 | |
| After day 90 | 0 | |
EPFX extended-pulsed fidaxomicin, EOT end of treatment, CDI Clostridium difficile infection